Tempus AI jumped 4% on ARK buying after tumbling 19% on Wednesday on short selling.
Ark Invest made a significant move by purchasing shares of Tempus AI Inc. across its ARK Genomic Revolution ETF and ARKK funds. The ARKG fund acquired 34,299 shares, while ARKK added 216,781 shares to its portfolio.
This acquisition comes at a time when Tempus AI is under scrutiny from Spruce Point Capital Management, a short seller that has raised concerns about the company’s management and accounting practices. The short seller’s report, titled “The Tempest Surrounding Tempus AI,” has contributed to a decline in Tempus AI’s stock price. Despite these challenges, Ark Invest’s purchase indicates a continued belief in Tempus AI’s potential within the AI sector.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.